HomeOpen Access NewsDrug Development

Drug Development

Oxford & GSK launch £50 million experimental medicine programme to prevent cancer

Oxford University and GSK launch a £50 million experimental medicine programme aiming to train the immune system to prevent cancer, paving the way for breakthrough vaccines and early‑stage treatments.

How clarity and standards can help the CBD Industry to thrive

Michael Sassano, CEO at SOMAÍ Pharmaceuticals, walks us through how clarity and standards can help the CBD Industry to thrive.

What is emotional ‘blunting’ and how does it affect depression?

Patients with depression on antidepressant drugs can experience ‘blunting’ – affecting both emotions and learning.

Day Tripper: is LSD and magic mushroom microdosing the future?

Kath Temple, Psychologist, discusses the history, politics and science behind LSD and magic mushroom microdosing.

Drug combination for children with MYC amplified Medulloblastoma

Researchers discover drug combination that could offer a better prognosis for children diagnosed with MYC amplified Medulloblastoma, an often deadly form of brain cancer.

Exploring the human epidermal growth factor receptor 2 (HER2)

Gail Dianne Lewis, the Senior Principal Scientist at Discovery Oncology Genentech, Inc. analyses the human epidermal growth factor receptor 2.

Degenerative eye disease and the opportunities of ophthalmic drug development

Eric Buckland of Translational Imaging Innovations looks at ophthalmic drug development and how better clinical endpoints can improve success rates.

Hemp & CBD – A legitimate industry framework

Here, Savage Cabbage Ltd argue for a legitimate Industry Framework when it comes to hemp & CBD

Increasing blood-brain barrier permeability with Acoustic Cluster Therapy (ACT®) to enhance drug delivery in the brain

Despite the rising incidence of Central Nervous System diseases worldwide, efficient treatment options for neurological disorders remain scarce. Treatment failures are principally associated with the inability of drugs to pass the highly selective Blood-Brain Barrier rather than a lack of efficacy.

The UK CBD Market: Cannabinoids, Consumers and Confusion

Savage Cabbage Ltd give insight into the UK CBD market, defining the differences in cannabinoid products and their roles in the industry.

Tackling antimicrobial resistance: A digital approach

Reflecting on the recent World Antimicrobial Awareness Week (WAAW 2022), it’s evident that we must continue to raise better awareness and understanding of antimicrobial resistance, which is one of the top 10 global public health threats facing humanity.

New drug ‘Lecanemab’ slows the effects of Alzheimer’s disease

After decades of failure for Alzheimer’s researchers, Lecanemab could open the door to a new ear of drugs to treat Alzheimer’s disease – the world's most common form of dementia.

Legalization of recreational cannabis linked with increased alcohol consumption

States that oversaw the legalization of recreational cannabis linked to increased alcohol consumption that is largely driven by young adults and men.

COVID-19, communicable disease and immunology

Academic Research Scholar, Prof Wendy M. Purcell, provides an update on COVID-19, communicable disease and immunology.

Ayahuasca dangers: mental and physical adverse effects

A survey looking at ayahuasca dangers finds 70% experience physical and 55% mental health adverse effects – but only 2.3% of physical adverse events require medical attention.

Hepatitis C virus elimination: A potential global success story

Dr Zisis Kozlakidis and Dr Dewi Nur Aisyah examine Hepatitis C virus elimination and weigh up if this has the potential to become a global success story.

Germany becomes one of the first European countries to legalise cannabis

Germany has made plans to legalise cannabis, which could create up to 27,000 new jobs and save around about 4.7 billion euros.

Advertisements


Latest Academic Articles

The latest academic articles from key research stakeholders